Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Embla Medical hf. (EMBLA.CO)
Reykjavík, ANT, IS
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.42% | +1.47% | +4.75% | -7.24% | -27.31% | -13.91% | -22.39% | -10.11% | -42.84% | +6.25% | +220.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+12.7% ★ Q1'26: +12.7% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+25.0% ★ Q1'26: +21.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+11.6% Q1'26: +2.2% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+13.2% ★ Q1'26: +9.7% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+6.6% ★ Q1'26: +5.0% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.1% Q1'26: -1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×3.65× Q1'26: 3.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
854.89M
est: 856.29M (-0.2%)
|
963.59M
est: 926.67M (+4.0%)
|
1.02B
1.01B – 1.02B
+9.7% YoY
|
1.10B
1.09B – 1.10B
+7.9% YoY
|
1.18B
1.17B – 1.19B
+7.9% YoY
|
1.27B
1.26B – 1.28B
+7.1% YoY
|
1.38B
1.37B – 1.39B
+9.2% YoY
|
| EBITDA |
169.78M
est: 148.48M (+14.4%)
|
189.89M
est: 160.68M (+18.2%)
|
176.19M
174.56M – 177.26M
+9.7% YoY
|
190.06M
188.84M – 191.24M
+7.9% YoY
|
205.16M
203.56M – 206.42M
+7.9% YoY
|
219.76M
218.05M – 221.11M
+7.1% YoY
|
239.87M
238.00M – 241.35M
+9.2% YoY
|
| EBIT |
113.81M
est: 104.29M (+9.1%)
|
126.99M
est: 112.87M (+12.5%)
|
123.76M
122.61M – 124.51M
+9.7% YoY
|
133.50M
132.64M – 134.33M
+7.9% YoY
|
144.11M
142.99M – 145.00M
+7.9% YoY
|
154.37M
153.16M – 155.32M
+7.1% YoY
|
168.49M
167.18M – 169.53M
+9.2% YoY
|
| Net Income |
68.28M
est: 77.08M (-11.4%)
|
86.47M
est: 83.16M (+4.0%)
|
94.49M
90.60M – 98.38M
+13.6% YoY
|
114.25M
108.65M – 119.85M
+20.9% YoY
|
124.28M
108.09M – 140.48M
+8.8% YoY
|
143.81M
142.35M – 144.97M
+15.7% YoY
|
166.98M
165.29M – 168.32M
+16.1% YoY
|
| SGA |
381.12M
est: 381.70M (-0.2%)
|
390.20M
est: 413.08M (-5.5%)
|
452.96M
448.75M – 455.70M
+9.7% YoY
|
488.59M
485.45M – 491.64M
+7.9% YoY
|
527.42M
523.31M – 530.67M
+7.9% YoY
|
564.96M
560.55M – 568.44M
+7.1% YoY
|
616.66M
611.85M – 620.46M
+9.2% YoY
|
| EPS |
0.16
est: 0.18 (-11.4%)
|
0.20
est: 0.19 (+2.6%)
|
0.23
0.21 – 0.23
+15.8% YoY
|
0.27
0.25 – 0.28
+18.0% YoY
|
0.30
0.25 – 0.33
+14.0% YoY
|
0.34
0.33 – 0.34
+10.8% YoY
|
0.39
0.39 – 0.39
+16.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sveinn Solvason | President & Chief Executive Officer | 7M | male |
| Olafur Gylfason | Executive Vice President of Chronic Solutions | 3M | male |
| Margret Lara Fridriksdottir | Executive Vice President of People, Strategy & Sustainability | 2M | female |
| Ossur Kristinsson | Founder | 160.3K | male |
| Klaus Sindahl | Head of Investor Relations | — | male |
| Andre Rocha | Executive Vice President of Research & Development | — | male |
| Lukas Marklin | Chief Operating Officer | — | male |
| Christian Robinson | President Americas & Global Bracing | — | male |
| Edda H. Geirsdottir | VP of Corporate Communications | — | — |
| Gudny Arna Sveinsdottir | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EMBLA.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
